A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
RV1729 is a new medicine being developed for possible treatment of asthma and smoking related
lung disease (also known as chronic obstructive pulmonary disease - COPD).
The main purpose of this study is to investigate the safety, tolerability and
pharmacokinetics of single and repeat doses of RV1729.